Novo Nordisk inks deal with Dewpoint Therapeutics to boost diabetes portfolio
The deal couples Novo Nordisk’s experience in diabetes with Dewpoint’s discovery and artificial intelligence platform. The companies will work to discover potential molecule drugs against multiple condensate targets.